Growth hormone axis
Mecasermin
Also called rhIGF-1, Increlex
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 13.33mg/mL
- Volume per draw
- 0.08mL
- Units to dial
- 8
- Doses per cartridge
- 37
Requested 0.075 mL
Requested 7.5
7.5 units is between clicks. The nearest setting is 8, which delivers 1.067 mg instead of 1 mg.
Vial label
Copy this into your label printer.
Published research contexts for Mecasermin describe 1–3 mg per administration. Descriptive only, not a recommendation.
About 5–6 hours; recombinant IGF-1 given twice daily with food.
Recombinant human IGF-1, dosed by body weight (0.04–0.12 mg/kg twice daily with food); the range shown is a representative per-dose amount, and dosing is titrated to limit hypoglycemia.
Dosing schedule
How Mecasermin is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Starting rangeTitrated by body weight; taken with food to limit hypoglycemia. | 0.04–0.08 mg/kg | Twice daily, with food | SubQ |
| Up toHighest weight-based step on the licensed label. | 0.12 mg/kg | Twice daily, with food | SubQ |
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.33× single dose
- Time to steady state
- 30hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Mecasermin (Increlex) product literatureRecombinant human IGF-1 licensed for severe primary IGF-1 deficiency; weight-based twice-daily dosing with food, titrated to limit hypoglycemia.